Previous 10 | Next 10 |
2023-07-28 17:37:13 ET Theratechnologies ( TSX: TH:CA ) ( NASDAQ: THTX ) said Friday that it amended some of the terms of its credit agreement entered into in July 2022. The amendment will lower the minimum liquidity the company must maintain at any time to US$15 million...
Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023 This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short ...
MONTREAL, July 21, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Gary Littl...
2023-07-20 08:32:26 ET Theratechnologies ( NASDAQ: THTX ) Board of Directors approved a one (1) post- consolidation share for each four pre-consolidation shares. The consolidation will be effective on July 31, 2023. The company expects its common shares to begin t...
- Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements This news release constitutes a “designated news release” fo...
2023-07-12 11:40:18 ET Theratechnologies Inc. (THTX) Q2 2023 Earnings Conference Call July 12, 2023, 08:30 AM ET Company Participants John Mullaly - LifeSci Advisors Paul Levesque - President and CEO Philippe Dubuc - SVP and CFO Christian Marsolais - SVP and ...
2023-07-12 07:36:29 ET Theratechnologies ( NASDAQ: THTX ): Q2 net loss of $10.01M Revenue of $17.5M (-9.2% Y/Y) misses by $4.63M . For further details see: Theratechnologies reports Q2 results
S udocetaxel zendusortide Phase 1 Trial to resume following FDA agreement to amended protocol Q2 2023 consolidated revenue were affected by specialty pharmacy inventory adjustments, and came in at $17.5 million FY2023 revenue guidance recast to fall within $82 ...
2023-07-07 11:08:15 ET Next week marks the start of a crucial period as earnings season kicks off, with major companies from the financial, consumer, and technology sectors all set to release their quarterly financial results. Among the list of firms scheduled to announce their financia...
MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report fina...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...